CGC. Gennigens

C. Gennigens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


C. Gennigens has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 April 2015
      • Vol. 70  (4) , 195-200

    [Management of febrile neutropenia in cancer patients].

    by P Freres, E Gonne, J Collignon, J B Giot, C Gennigens, G Jerusalem

    The incidence of cancer is raising and the treatments are increasingly aggressive. Consequently, general practitioners, emergency departments, hematologists and oncologists are regularly facing a severe side-effect of cytotoxic therapy, febrile neutropenia (FN). FN is a serious complication of chemotherapy because it can be quickly fatal and causes a temporary or definitive cessation of treatment. In this article, we summarize the latest recommendations for the management of patients with FN under anti-cancer treatments.

    • 1 January 2014
      • p. 63-8

    [Multidisciplinary treatment of glioblastoma].

    by N Barthelemy, C Gennigens, F Scholtes, L Tshibanda, B Otto, P Piret, D Martin, G Jérusalem, P Coucke

    Glioblastoma is a primary brain tumor that occurs most often in elderly patients. Despite improved management, the prognosis of this cancer remains poor. This review describes the multidisciplinary management of the patient with glioblastoma. It includes surgery, radiation therapy and chemotherapy.

    • 1 November 2013
      • Vol. 68  (11) , 557-61

    [Clinical case of the month. Ovarian cancer metastasis to the pectoral muscle].

    by A Benoit, G Jerusalem, C Gennigens

    We report the case of a patient with a sero-papillary ovarian cancer and a pectoral muscle metastasis. Muscular metastases are more common than previously suspected; any physician could encounter this type of case in his daily practice. This paper summarizes the literature on the subject.

    • 1 February 2013
      • Vol. 68  (2) , 94-6

    [New treatments for castration-resistant prostate cancer].

    by B Sautois, C Gennigens

    Docetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line treatment may be appropriate. Until recently no standard treatment was approved in this setting and mitoxantrone was commonly used. Three new drugs have shown benefit in randomised phase 3 multicenter clinical trials published since 2010. Cabazitaxel, abiraterone and enzalutamide were shown to prolong overall survival of men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. Although still modest these results were deemed clinically significant and led to the reimbursement of Jevtana (cabazitaxel) and Zytiga (abiraterone) in Belgium in 2012.

    • 1 November 2012
      • Vol. 67  (11) , 582-6

    [Peritoneal carcinomatosis of unknown origin].

    by N Marchal, C Gennigens, G Jerusalem

    Peritoneal carcinomatosis is defined as a secondary neoplastic invasion of the peritoneum. This entity may represent a significant challenge in terms of its diagnosis, its exploration and research of its origin and its treatment. This clinical history illustrates the difficulties generated by a case of peritoneal carcinomatosis and describes the importance of a multidisciplinary approach. When the primary origin is unknown before the initiation of treatment, the peritoneal carcinomatosis is a form of carcinoma of unknown primary (CUP). When this condition affects a woman, it becomes a particular entity with a better outcome, for which a specific first-line treatment should be initiated.


    • 19 September 2012
      • Vol. 67, 437-42

    [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].

    by C Gennigens, G Jerusalem

    Renal cell carcinoma accounts for 3% of all malignant tumors. Until a few years ago, immunotherapy (Interferon and/or Interleukin-2) was the only approved systemic treatment in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF and VEGFR inhibitors. They are now the standard treatment in first and second line. Pazopanib, a VEGFR tyrosine kinase inhibitor, is one of the treatment options recommended for patients with metastatic renal cell carcinoma, in first line and after cytokines failure. Since more recently, pazopanib is also approved in the treatment of metastatic soft tissue sarcoma, after failure of at least one line of chemoterapy. In this paper, we will review the mechanism of action and the clinical results of pazopanib in renal cell carcinoma and sarcoma.


    • 29 September 2011
      • Vol. 66, 452-5

    [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].

    by C Gennigens, G Jerusalem

    Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has proven its efficacy after failure of standard treatments: the trabectedin; its activity is based on interference with ADN repair mechanisms. Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin.

    • 1 April 2010
      • Vol. 65  (4) , 212-6

    [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].

    by C Gennigens, B Sautois, G Jerusalem

    Renal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, immunotherapy (interferon and/or interleukin-2) was the only approved option in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF ("Vascular Endothelial Growth Factor") and VEGFR inhibitors. They are now the usual treatment in first line. Until recently, no standard treatment was available after failure under or after these inhibitors. Everolimus (Afinitor), a mTOR ("mammalian Target Of Rapamycin") inhibitor, has just been validated and reimbursed in this setting. In this paper, we will review the mechanism of action and the clinical results of everolimus.


    • 1 March 2010
      • Vol. 65  (3) , 120-6

    ["Triple negative" breast cancer].

    by P Freres, J Collignon, C Gennigens, I Scagnol, A Rorive, A Barbeaux, P A Coucke, G Jérusalem

    In western countries, every woman out of eight will develop breast cancer. Over the last two decades, the incidence has considerably increased, but mortality has remained stable and begins to decrease in Europe and the United-States, probably because of new therapy, changes in the use of hormone replacement therapy in postmenopausal women and early diagnosis. Breast cancer is still the first cause of death by cancer in woman under 65. "Triple negative" a breast cancer, a subtype representing 10% of all breast cancers, is characterised by the absence of receptors to oestrogen, progesterone and no histochemical expression of HER-2 growth factor. This subtype carries a poor prognosis and a high incidence of early metastatic recurrence. Furthermore, no target therapy can be defined up to now in this subtype. Thus, identification of new target therapy and prediction of tumoral response to various treatments could help in the global understanding of patients affected by this particularly aggressive type of breast cancer.


    • 26 September 2009
      • Vol. 64, 409-13

    [Angiosarcoma in chronic lymphoedema: a case of Stewart-Treves syndrome].

    by E Gonne, J Collignon, W Kurth, A Thiry, F Henry, G Jerusalem, C Gennigens

    The Stewart-Treves Syndrome is defined as an angiosarcoma (very aggressive malignant tumor originating from endothelial cells) appearing in a specific clinical setting. This tumor develops in patients suffering from chronic lymphedema of the upper limb following mastectomy and axillary lymph node dissection for breast cancer. The diagnosis relies on medical history, clinical examination and a histological assesment (biopsy or resection). This syndrome represents a rare clinical entity. Unfortunately, the prognosis is poor. A large surgical resection is the treatment of choice if the patient is a candidate for a surgical resection with a curative intent Radiotherapy is sometimes used as a palliative local treatment. Chemotherapy is only used in more advanced cases, not curable by surgery alone.